Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;44(2):237-249.
doi: 10.1007/s13402-020-00578-6. Epub 2021 Jan 19.

Clinical perspectives of BET inhibition in ovarian cancer

Angeliki Andrikopoulou  1   2 , Michalis Liontos  1   2 , Konstantinos Koutsoukos  1   2 , Meletios-Athanasios Dimopoulos  1   2 , Flora Zagouri  3   4
Affiliations
Review

Clinical perspectives of BET inhibition in ovarian cancer

Angeliki Andrikopoulou et al. Cell Oncol (Dordr). 2021 Apr.

Abstract

Background: Bromodomain and extra-terminal (BET) proteins are epigenetic readers that bind to acetylated lysines of histones and regulate gene transcription. BET protein family members mediate the expression of various oncogenic drivers in ovarian cancer, such as the MYC and Neuregulin 1 (NRG1) genes. BRD4, the most thoroughly studied member of the BET family, is amplified in a significant subset of high-grade serous carcinomas (HGSC) of the ovary. It has been reported that BET inhibitors can attenuate the proliferation and dissemination of ovarian cancer cells by inhibiting oncogenic pathways, such as the FOXM1 and JAK/STAT pathways. BET inhibition can re-sensitize resistant ovarian cancer cells to already approved anticancer agents, including cisplatin and PARP inhibitors. This synergism was also confirmed in vivo in animal models. These and other preclinical results provide a promising basis for the application of BET inhibitors in ovarian cancer treatment. Currently, Phase I/II clinical trials explore the safety and efficacy profiles of BET inhibitors in various solid tumors, including ovarian tumors. Here, we review current knowledge on the molecular effects and preclinical activities of BET inhibitors in ovarian tumors.

Conclusions: BET proteins have emerged as new druggable targets for ovarian cancer. BET inhibitors may enhance antitumor activity when co-administered with conventional treatment regimens. Results from ongoing Phase I/II studies are anticipated to confirm this notion.

Keywords: BET inhibitors; BET proteins; Bromodomain; Epigenetic treatment; High-grade serous carcinoma; Ovarian cancer.

PubMed Disclaimer

References

    1. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020. CA Cancer J Clin 70, 7–30 (2020)
    1. J. Prat, New insights into ovarian cancer pathology. Ann Oncol 23 (Suppl 10), x111–x117 (2012) - PubMed
    1. U.A. Matulonis, A.K. Sood, L. Fallowfield, B.E. Howitt, J. Sehouli, B.Y. Karlan, Ovarian cancer. Nat Rev Dis Primers 2, 1–22 (2016)
    1. N.H. Chobanian, V.L. Greenberg, J.M. Gass, C.P. Desimone, J.R. Van Nagell, S.G. Zimmer, Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res 24, 539–545 (2004) - PubMed
    1. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, I. Felletar, M. Philpott, S. Munro, M.R. McKeown, Y. Wang, A.L. Christie, N. West, M.J. Cameron, B. Schwartz, T.D. Heightman, N. La Thangue, C.A. French, O. Wiest, A.L. Kung, S. Knapp, J.E. Bradner, Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010) - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources